Terapia omalizumabem u pacjentki z ciężką eozynofilową astmą alergiczną i bólem stawów występującym podczas terapii – opis przypadku

Implementation of omalizumab in the treatment of patients with severe allergic asthma opened the possibility of obtaining optimal control of the disease and improving the quality of life. We present a case of a patient with severe allergic asthma qualified to biological treatment with omalizumab. Before qualification, the patient suffered from numerous severe exacerbations and uncontrolled asthma symptoms, despite treatment with high doses of inhaled medications and systemic corticosteroids. After 2 years of biological therapy, we achieved a significant, but incomplete improvement in asthma control, a marked improvement in the quality of life, and a decrease in the number of exacerbations. We observed persistent elevation of eosinophilia in peripheral blood and bronchoalveolar lavage, despite treatment with anti-IgE and systemic corticosteroids, indicating eosinophil phenotype of severe asthma. Moreover, in the course of therapy, the patient reported joint symptoms of unknown origin, which after further testing were eventually attributed to post-steroid complications and osteoarthritis. In appropriately qualified patients, treatment with omalizumab gives hope for significant improvement in asthma control. The development of new biological agents will allow individualizing asthma treatment depending on asthma phenotype and endotype.